Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 21 for “"Drug-induced liver injury"”.
-
The natural history of Efavirenz Drug Induced liver injury
… natural history of the previously reported EFV drug induced liver injury (DILI), is unknown. Objectives To establish causality assessment for the drug-induced liver injury and elucidate the natural history of EFV DILI by observing a cohort of patients through documenting all the factors …
-
Human Liver Organoids as models for investigating drug-induced liver injury
The liver is the primary organ involved in drug detoxification, hence being highly exposed to the risk of drug induced liver injury (DILI). DILI is the main cause for acute liver failure in western countries and post-marketing withdrawal of drugs. This is highly due to the poor identification of …
-
N-Acetylcysteine for non-paracetamol drug-induced liver injury: A systemic review
Aims: There are limited therapeutic options for drug-induced liver injury (DILI). N-acetylcysteine (NAC ) is known to be of benefit in management of DILI due to paracetamol overdose and may also be useful in the management of non-paracetamol DILI. Our objective was to systematically review evidence …
-
Development of circulating microRNA in drug-induced liver injury: studies in humans and zebrafish
… used as biomarkers in patients with paracetamol-induced liver injury. Whether the miRNAs discovered in humans could be back-translated to zebrafish with the aim of developing a liver toxicity model to replace rodent use was also investigated. First, the miRNA signature of DILI induced by …
-
Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa
… present with TB treatment and or ART-associated drug-induced liver injury (DILI) amongst all patients presenting with significant liver injury to GF Jooste Hospital during the study period. 2. To describe base line clinical characteristics and management of TB treatment and or ART-associated DILI …
-
Using free-text searching and ICD-10 codes to identify prospective patients with drug-induced liver injury
<p>Drug-induced liver injury (DILI) is a rare cause of liver disease that is difficult to diagnose due to the lack of a confirmatory test. The Drug-Induced Liver Injury Network (DILIN) was developed to enroll patients with DILI to understand the clinical outcomes of the disease. The present study …
-
A randomised controlled trial of N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury
Background: Liver injury is the most common severe adverse effect of first-line anti-tuberculosis therapy (ATT). Nacetylcysteine (NAC) has efficacy in patients with paracetamol toxicity, and may be of benefit in liver injury due to other causes, such as ATT-induced liver injury (AT-DILI). …
-
Liver Injury in HIV-positive Patients on Antituberculosis and/or Antiretroviral Therapy – Assessing Causality
… expert panel review in identifying a drug-induced liver injury (DILI) due to antituberculosis therapy (ATT) and/or antiretroviral therapy (ART). Methods Cases were drawn from a prospective registry of hospitalised adults with suspected DILI due to ATT and/or ART in Cape Town, South …
-
Using transcriptomic data to detect, understand, and treat injury in the context of drug toxicity and fibrotic disease
In drug discovery, it is crucial to understand how drugs relate to complex phenotypes. This includes understanding how a drug can help to treat a condition, but also how it can result in adverse effects so that safety risks can be mitigated earlier. How effects propagate from the molecular to the …
-
Engineering Liver and Cardiac Models for Drug Development and Regenerative Medicine
… data for preclinical evaluations of drug-induced liver injury and cardiotoxicity, speeding up the notoriously lengthy and inefficient drug development pipeline, as well as fundamental investigations into stem cell behavior and cell-cell interactions. Tissue engineering is also …
-
Engineering complex liver models for drug screening and infectious diseases: a biomaterials and co-culture perspective
In vitro liver models have many applications in disease modeling and drug screening. Micropatterned cocultures (MPCCs) of primary human hepatocytes (PHHs) and supportive stromal cells have been shown to display high hepatic functions for long-term drug and disease studies. However, MPCCs lack liver …
-
Development of 3D multicellular liver organoids derived from human induced pluripotent stem cells to model antiretroviral therapy induced liver injury
Introduction: The liver is an essential organ in the body responsible for the synthesis of serum proteins, biotransformation, and detoxification of xenobiotic drugs. Drug cytotoxicity studies have been conducted using cancer-derived cell lines which are inferior. In the present study, we developed …
-
Citrobacter rodentium induced liver changes in C57BL/6 mice : animal model of acute inflammatory stress and injury
… for host defense, contributes to hepatic injury in numerous acute and chronic liver disease states as well as drug-induced liver injury (DILI). The interactions that mediate susceptibility to liver injury and disease, however, are still poorly understood, underscored by the complexity of …
-
Understanding compound-induced histopathology in rat liver using gene expression network methods
Current drug discovery is a lengthy and costly pipeline; it takes between twelve and fifteen years and costs $1-2 billion (USD). As such, any compound failures represent a sunk cost – exacerbated if such failures occur later in the pipeline. Compound and drug induced liver injury is a significant …
-
Understanding the transport mechanisms of BSEP to improve the prediction of DILI compounds
At present, Drug-Induced Liver Injury (DILI) is the most frequent cause of acute liver injury, with an incidence ranging from 0.023-1.5‰ in developed countries. DILI can be separated into two different types. Whereas intrinsic DILI concerns predictable dose-dependent hepatoxicity, idiosyncratic …
-
Engineered microtissue platforms for modeling human pathophysiology and drug metabolism
Over 50% of all drug candidates entering clinical trials are abandoned due to insufficient efficacy or unexpected safety issues despite extensive pre-clinical testing. Liver metabolites that cause toxicity or other side effects cannot always be predicted in animals, in part because of …
-
Combining a microfluidic platform with LC-MS for the detection of induced hepatotoxicity using primary hepatic spheroids
The success rate of bringing a new drug from conception to market is extremely low as well as time consuming and very costly. Simple sub-cellular models can provide high throughput data allowing early detection of many drugs doomed to fail, but do not encompass the complexity found in whole cell …
-
Identification of a gap junction communication pathway critical in innate immunity
… response. At the onset of infection or sterile injury, individual cells sense danger or damage signals and elicit innate immune responses that spread from the challenged cells to surrounding cells, thereby establishing an overall inflammatory state. However, little is known about how these …
-
Integrated imaging and circulating biomarkers for the assessment of drug-induced hepatotoxicity
Drug-induced liver injury (DILI) is a major burden for health care systems and a principal reason for attrition during drug development. Prediction of clinical DILI remains difficult and diagnosis is usually based on exclusion using blood-based biomarkers for cell injury. Currently used chemistry …
-
Quantitative pharmacoproteomics investigation of anti-cancer drugs in mouse. Development and optimisation of proteomics workflows for evaluating the effect of anti-cancer drugs on mouse liver
Minimizing anti-cancer drug toxicity is a major challenge for the pharmaceutical industry. Toxicity is most frequently due to either the direct interaction of the drug on previously unidentified targets or its conversion to metabolites by drug metabolizing enzymes (e.g. CYP450 enzymes) that cause …
Page 1 of 2